Gibbs Lab

29/10/2025

Prof. Peter Gibbs has been elected Fellow of The Australian Academy of Health and Medical Sciences (AAHMS) for his contributions to cancer research.

Each year, the AAHMS Fellowship elects the best and brightest minds in Australia to join the Academy in recognition of their outstanding achievement and ongoing contribution in the field of medical and health sciences.

“... This is an incredible honour for me personally. However, this Fellowship is also recognition of the collective hard work and perseverance of my laboratory team.” - Prof. Peter Gibbs

This Fellowship is a testament to Prof. Gibbs’ 20+ years of experience in clinical research and translational medicine and his contributions to the development of personalised treatments for patients with bowel cancer.

The full story and interview with Prof. Gibbs can be found here:

WEHI’s Professor Peter Gibbs has been elected Fellow of The Australian Academy of Health and Medical Sciences (AAHMS) for his pioneering contributions to cancer research.

28/10/2025

This presentation at represents the culmination of many years of incredible work by Prof. Jeanne Tie and the team. 🔥

Recently published in Nature Medicine, the DYNAMIC-III study is a multi-centre, randomised, phase II/III trial. Patients with stage III colon cancer underwent ctDNA testing post-surgery and were assigned to ctDNA-guided or standard management treatment.

🔍 ctDNA is a validated prognostic classifier and can serve as a sensitive, non-invasive biomarker to guide adjuvant chemotherapy.

🔍 Read more about the study here: https://bioengineer.org/detecting-colon-cancer-dna-in-blood-could-inform-chemotherapy-choices-study-finds/

Or check out the full Nature publication: https://www.nature.com/articles/s41591-025-04030-w

23/09/2025

Amazing work by Dr Lucy Gately from at . Her presentation on the EMBRACE program won Most Outstanding Oral Presentation 🌟

The EMBRACE program is working to enhance multi-site brain cancer research, utilising the BRAIN Registry and results from the BioBrain project.

🔎 The BioBrain project is a robust biobank of brain cancer tissue, used to explore the use and creation of organoid models, help guide treatment selection and potentially identify novel treatments for patients.

🔎 The BRAIN Registry is exploring how brain cancer is diagnosed and treatment across Australia, from initial presentation to outcomes and survival rates.

A fabulous example by Dr Gately of how the research can be utilised to answer novel research questions. 🌟

22/08/2025

Congratulations to Dr Grace Gard of the for winning the best oral prize at MOGA ASM 2025 for her presentation on understanding motivations of patient participation in research or in considering unfunded medication. 🌟

This interesting research came out of the CO-DESIGN study, a survey investigating consumer perspectives and involvement in clinical research. The study captured a cross-section of community views on the consumer experience and we learned that:

🔎 The potential benefit for future patients is a major driver to trial participation.

🔎 Reimbursement alone may not drive broader representation and participation in trials. Further research is needed to better understand how funding plays into participation.

07/08/2025

🔍Check out some of the amazing research that has been done utilising the ARORA Registry data!

Presented at Breast Cancer Trials 2025 ASM last week, this poster reflects one of the registries in action. The ARORA Registry commenced in 2020 and tracks HR+, HER2+ advanced breast cancer patients across Australia from presentation to treatment and outcomes.

Utilising ARORA data, this new research has been able to validate clinical trial data and will help guide treatment decisions in routine care. Fabulous to see this great use of registries.👏